Viridian Therapeutics Inc (VRDN)

12:50 PM

Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts - ts2.tech

12:50 PM

11:09 AM

Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus

11:09 AM

10:55 AM

Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease - GuruFocus

10:55 AM

10:49 AM

Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week HighShould You Buy? - MarketBeat

10:49 AM

10:25 AM

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga

10:25 AM

10:18 AM

Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com

10:18 AM

03:00 AM

Viridian Therapeutics (NASDAQ:VRDN) Builds Targeted Antibody Programs - Kalkine Media

03:00 AM

Dec 12, 2025

Understanding Momentum Shifts in (VRDN) - news.stocktradersdaily.com

Dec 12, 2025

Dec 12, 2025

Maverick Capital Ltd. Grows Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 12, 2025

Dec 11, 2025

Viridian Therapeutics, Inc. $VRDN Shares Sold by Walleye Capital LLC - MarketBeat

Dec 11, 2025

Dec 11, 2025

HighVista Strategies LLC Has $6.77 Million Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 11, 2025

Dec 10, 2025

Velan Capital Investment Management LP Makes New $1.21 Million Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 10, 2025

Dec 10, 2025

Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Wedbush - MarketBeat

Dec 10, 2025

Dec 10, 2025

Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating - marketscreener.com

Dec 10, 2025

Dec 10, 2025

VRDN: Wedbush Raises Price Target to $47 While Maintaining Outpe - GuruFocus

Dec 10, 2025

Dec 10, 2025

Viridian Therapeutics, Inc. $VRDN Stock Position Lifted by Marshall Wace LLP - MarketBeat

Dec 10, 2025

Dec 10, 2025

Diadema Partners LP Has $1.71 Million Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 10, 2025

Dec 08, 2025

With Viridian Therapeutics Stock Surging, Have You Considered The Downside? - Trefis

Dec 08, 2025

Dec 06, 2025

What analysts say about Viridian Therapeutics Inc stockEarnings Growth Projections & High Return Capital Gain - earlytimes.in

Dec 06, 2025

Dec 05, 2025

Evaluating Viridian Therapeutics (VRDN) After William Blair’s New ‘Outperform’ Rating and Rising Investor Optimism - Sahm

Dec 05, 2025

Dec 05, 2025

Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighWhat's Next? - MarketBeat

Dec 05, 2025

Dec 05, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 5, 2025 - BioSpace

Dec 05, 2025

Dec 05, 2025

Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com

Dec 05, 2025

Dec 04, 2025

Why Viridian Therapeutics Inc. (1S1) stock fits value portfolios2025 AllTime Highs & Smart Allocation Stock Tips - Newser

Dec 04, 2025

Dec 04, 2025

Viridian Therapeutics stock hits 52-week high at 32.58 USD By Investing.com - Investing.com Canada

Dec 04, 2025

Dec 04, 2025

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Sahm

Dec 04, 2025

Dec 04, 2025

Viridian Therapeutics stock hits 52-week high at 32.58 USD - Investing.com India

Dec 04, 2025

Dec 04, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025

Dec 04, 2025

How Viridian Therapeutics Inc. (1S1) stock gains from tech spendingMarket Sentiment Summary & Daily Chart Pattern Signal Reports - Newser

Dec 04, 2025

Dec 04, 2025

Can Viridian Therapeutics Inc. (1S1) stock retain market dominanceJuly 2025 Breakouts & Safe Entry Point Identification - Newser

Dec 04, 2025

Dec 04, 2025

Will William Blair’s Outperform Initiation Shift Viridian Therapeutics’ (VRDN) Narrative Among Institutional Investors? - Sahm

Dec 04, 2025

Dec 04, 2025

How analysts revise price targets for Viridian Therapeutics Inc. (1S1) stockJuly 2025 Final Week & High Yield Stock Recommendations - Newser

Dec 04, 2025

Dec 04, 2025

Is Viridian Therapeutics Inc. (1S1) stock suitable for passive index fundsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - Newser

Dec 04, 2025

Dec 03, 2025

William Blair Initiates Coverage of Viridian Therapeutics (VRDN) with Outperform Recommendation - Nasdaq

Dec 03, 2025

Dec 03, 2025

William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN Stock News - GuruFocus

Dec 03, 2025

Dec 03, 2025

William Blair Initiates Viridian Therapeutics at Outperform - marketscreener.com

Dec 03, 2025

Dec 02, 2025

Why Viridian Therapeutics Inc. (1S1) stock is favored by hedge fundsTrade Exit Summary & Detailed Earnings Play Alerts - Newser

Dec 02, 2025

Dec 02, 2025

Loomis Sayles & Co. L P Sells 31,884 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 02, 2025

Dec 01, 2025

Avoiding Lag: Real-Time Signals in (VRDN) Movement - news.stocktradersdaily.com

Dec 01, 2025

Dec 01, 2025

Geode Capital Management LLC Purchases 20,089 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat

Dec 01, 2025

Nov 30, 2025

Will Viridian Therapeutics Inc. stock attract more institutional investorsTrade Exit Summary & Real-Time Volume Analysis - BỘ NỘI VỤ

Nov 30, 2025

Nov 28, 2025

Viridian Therapeutics (VRDN): Revisiting Valuation After Analyst Upgrades and Robust Revenue Growth - Sahm

Nov 28, 2025

Nov 28, 2025

Will Viridian Therapeutics Inc. stock continue upward momentumMarket Risk Summary & Breakout Confirmation Trade Signals - BỘ NỘI VỤ

Nov 28, 2025

Nov 28, 2025

Intech Investment Management LLC Reduces Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Nov 28, 2025

Nov 25, 2025

Viridian Therapeutics (NASDAQ:VRDN) Sets New 1-Year HighShould You Buy? - MarketBeat

Nov 25, 2025

Nov 24, 2025

Truist Securities Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq

Nov 24, 2025

Nov 24, 2025

Truist Securities Initiates Coverage on VRDN with Buy Rating | V - GuruFocus

Nov 24, 2025

Nov 24, 2025

Truist Securities initiates coverage on Viridian Therapeutic stock with Buy rating - Investing.com Canada

Nov 24, 2025

Nov 24, 2025

Why Viridian Therapeutics Shares Are Climbing Higher - TipRanks

Nov 24, 2025

Nov 22, 2025

Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues - simplywall.st

Nov 22, 2025

Nov 21, 2025

Viridian Therapeutics Inc. (VRDN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 21, 2025

Nov 21, 2025

Viridian Therapeutics stock hits 52-week high at $30.15 By Investing.com - Investing.com Nigeria

Nov 21, 2025

Nov 21, 2025

Viridian Therapeutics stock hits 52-week high at $30.15 - Investing.com India

Nov 21, 2025

Nov 20, 2025

Discipline and Rules-Based Execution in VRDN Response - news.stocktradersdaily.com

Nov 20, 2025

Nov 20, 2025

Is Viridian Therapeutics Inc. stock attractive for hedge fundsDollar Strength & Stepwise Entry and Exit Trade Signals - newser.com

Nov 20, 2025

Nov 20, 2025

Is Viridian Therapeutics Inc. stock cheap at current valuation2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com

Nov 20, 2025

Nov 20, 2025

How Viridian Therapeutics Inc. (1S1) stock compares with top peersJuly 2025 Action & Verified Swing Trading Watchlist - newser.com

Nov 20, 2025